Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

DCPH

Deciphera Pharmaceuticals (DCPH)

Deciphera Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:DCPH
FechaHoraFuenteTítuloSímboloCompañía
22/05/202406:01Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
13/05/202405:32Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
13/05/202405:31Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
10/05/202406:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
06/05/202416:16Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
29/04/202406:00Business WireDeciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 BillionNASDAQ:DCPHDeciphera Pharmaceuticals Inc
09/04/202406:00Business WireDeciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology ForumNASDAQ:DCPHDeciphera Pharmaceuticals Inc
27/02/202406:00Business WireDeciphera Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
20/02/202415:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
14/02/202415:06Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
07/02/202406:52Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DCPHDeciphera Pharmaceuticals Inc
07/02/202406:11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
06/02/202406:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DCPHDeciphera Pharmaceuticals Inc
06/02/202406:00Business WireDeciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
01/02/202415:50Business WireDeciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024NASDAQ:DCPHDeciphera Pharmaceuticals Inc
01/02/202406:00Business WireDeciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:DCPHDeciphera Pharmaceuticals Inc
18/01/202410:13Business WireDeciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers SymposiumNASDAQ:DCPHDeciphera Pharmaceuticals Inc
08/01/202406:00Business WireDeciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product CompanyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
05/01/202406:00Business WireDeciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18NASDAQ:DCPHDeciphera Pharmaceuticals Inc
02/01/202406:00Business WireDeciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:DCPHDeciphera Pharmaceuticals Inc
30/11/202317:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
29/11/202306:00Business WireDeciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology SummitNASDAQ:DCPHDeciphera Pharmaceuticals Inc
30/10/202306:01Business WireDeciphera Pharmaceuticals Announces Third Quarter 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
30/10/202306:00Business WireDeciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCTNASDAQ:DCPHDeciphera Pharmaceuticals Inc
29/09/202308:00PR Newswire (Canada)Medison Pharma Announces Public Formulary Listing of QINLOCK® (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) TreatmentNASDAQ:DCPHDeciphera Pharmaceuticals Inc
15/09/202316:00Business WireDeciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
05/09/202315:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
09/08/202306:00Business WireDeciphera Pharmaceuticals Announces Second Quarter 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
03/08/202315:15Business WireDeciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific OfficerNASDAQ:DCPHDeciphera Pharmaceuticals Inc
02/08/202306:00Business WireDeciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023NASDAQ:DCPHDeciphera Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:DCPH

Su Consulta Reciente

Delayed Upgrade Clock